drugset
drugset / Trial / NCT05824325

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

NCT05824325 ↗

Phase 1/2 Active not recruiting 56 enrolled Fudan University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phaseⅠb/Ⅱ, open-label, two-arm parallel study evaluating the efficacy and safety of different targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer

Timeline

Start
2023-03-14
Primary completion
2025-04-10
Completion
2026-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab Rezetecan Monoclonal antibody — —

Indications

breast cancer